A study led by Manel Esteller of Barcelona’s Institute of Biomedical Research of Bellvitge has identified a drug that inhibits cancer growth by activating the genome’s so-called “dark matter” (or non-coding DNA) and microRNA molecules. The study is published in Proceedings of the National Academy of Sciences

STAFF | MARCH 2ND, 2011

A study by researchers at the Barcelona’s Bellvitge Institute of Biomedical Research (Idibell) is the most often cited work in the category of Biology, according to the latest Science Watch rankings for the months of November and December produced by the news agency Thomson Reuters

STAFF | DECEMBER 27TH, 2010

In a subgroup of tumors that appear in the colon, stomach and uterus cancer cells hijack a group of anti-tumor molecules within the nucleus, preventing them from maturing and performing their function in the cell, according to an international team led by Manel Esteller, researcher of the Bellvitge Institute of Biomedical Research in Barcelona.

STAFF | OCTOBER 20TH, 2010

A study published in the journal Proceedings of the National Academy of Sciences (PNAS) shows a mechanism that explains the common properties shared by stem cells and cancer cells. The work has been made by the Cancer Epigenetics Research Group, led by Manel Esteller, ICREA researcher at Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona (UB).

STAFF | AUGUST 23 TH, 2010